Suresh Vedantham1, Samuel Z Goldhaber1, Jim A Julian1, Susan R Kahn1, Michael R Jaff1, David J Cohen1, Elizabeth Magnuson1, Mahmood K Razavi1, Anthony J Comerota1, Heather L Gornik1, Timothy P Murphy1, Lawrence Lewis1, James R Duncan1, Patricia Nieters1, Mary C Derfler1, Marc Filion1, Chu-Shu Gu1, Stephen Kee1, Joseph Schneider1, Nael Saad1, Morey Blinder1, Stephan Moll1, David Sacks1, Judith Lin1, John Rundback1, Mark Garcia1, Rahul Razdan1, Eric VanderWoude1, Vasco Marques1, Clive Kearon1. 1. From the Washington University School of Medicine, St. Louis (S.V., L.L., J.R.D., P.N., M.C.D., N.S., M.B.); Brigham and Women's Hospital, Harvard Medical School (S.Z.G.), and Massachusetts General Hospital, Harvard Medical School (M.R.J.) - all in Boston; McMaster University, Hamilton, ON (J.A.J., M.F., C.-S.G., C.K.), and McGill University, Jewish General Hospital, Montreal (S.R.K.) - all in Canada; the University of Missouri, St. Luke's Mid America Heart Institute, Kansas City (D.J.C., E.M.); St. Joseph's Vascular Institute, Orange (M.K.R.), and University of California, Los Angeles, Los Angeles (S.K.) - both in California; University of Michigan, Ann Arbor (A.J.C.); Cleveland Clinic Heart and Vascular Institute, Cleveland (H.L.G.); Rhode Island Hospital, Brown University, Providence (T.P.M.); Central DuPage Hospital, Winfield, IL (J.S.); University of North Carolina, Chapel Hill (S.M.); Reading Hospital, Reading, PA (D.S.); Henry Ford Hospital, Detroit (J.L.); Holy Name Hospital, Teaneck, NJ (J.R.); Christiana Care Hospital, Newark, DE (M.G.); St. Elizabeth's Regional Medical Center, Lincoln, NE (R.R., E.V.); and Pepin Heart Center, Tampa, FL (V.M.).
Abstract
BACKGROUND: The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome. METHODS: We randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or maceration, with or without stenting). The primary outcome was development of the post-thrombotic syndrome between 6 and 24 months of follow-up. RESULTS: Between 6 and 24 months, there was no significant between-group difference in the percentage of patients with the post-thrombotic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P=0.56). Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P=0.049), but no significant difference in recurrent venous thromboembolism was seen over the 24-month follow-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P=0.04). Severity scores for the post-thrombotic syndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 18, and 24 months of follow-up (P<0.01 for the comparison of the Villalta scores at each time point), but the improvement in quality of life from baseline to 24 months did not differ significantly between the treatment groups. CONCLUSIONS: Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; ATTRACT ClinicalTrials.gov number, NCT00790335 .).
BACKGROUND: The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome. METHODS: We randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or maceration, with or without stenting). The primary outcome was development of the post-thrombotic syndrome between 6 and 24 months of follow-up. RESULTS: Between 6 and 24 months, there was no significant between-group difference in the percentage of patients with the post-thrombotic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P=0.56). Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P=0.049), but no significant difference in recurrent venous thromboembolism was seen over the 24-month follow-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P=0.04). Severity scores for the post-thrombotic syndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 18, and 24 months of follow-up (P<0.01 for the comparison of the Villalta scores at each time point), but the improvement in quality of life from baseline to 24 months did not differ significantly between the treatment groups. CONCLUSIONS: Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; ATTRACT ClinicalTrials.gov number, NCT00790335 .).
Authors: Suresh Vedantham; Patricia E Thorpe; John F Cardella; Clement J Grassi; Nilesh H Patel; Hector Ferral; Lawrence V Hofmann; Bertrand M Janne d'Othée; Vittorio P Antonaci; Elias N Brountzos; Daniel B Brown; Louis G Martin; Alan H Matsumoto; Steven G Meranze; Donald L Miller; Steven F Millward; Robert J Min; Calvin D Neithamer; Dheeraj K Rajan; Kenneth S Rholl; Marc S Schwartzberg; Timothy L Swan; Richard B Towbin; Bret N Wiechmann; David Sacks Journal: J Vasc Interv Radiol Date: 2006-03 Impact factor: 3.464
Authors: Jacob Cynamon; Evan G Stein; R Joshua Dym; Marcy B Jagust; Christoph A Binkert; Richard A Baum Journal: J Vasc Interv Radiol Date: 2006-06 Impact factor: 3.464
Authors: Susan R Kahn; Stan Shapiro; Philip S Wells; Marc A Rodger; Michael J Kovacs; David R Anderson; Vicky Tagalakis; Adrielle H Houweling; Thierry Ducruet; Christina Holcroft; Mira Johri; Susan Solymoss; Marie-José Miron; Erik Yeo; Reginald Smith; Sam Schulman; Jeannine Kassis; Clive Kearon; Isabelle Chagnon; Turnly Wong; Christine Demers; Rajendar Hanmiah; Scott Kaatz; Rita Selby; Suman Rathbun; Sylvie Desmarais; Lucie Opatrny; Thomas L Ortel; Jeffrey S Ginsberg Journal: Lancet Date: 2013-12-06 Impact factor: 79.321
Authors: Suresh Vedantham; Samuel Z Goldhaber; Susan R Kahn; Jim Julian; Elizabeth Magnuson; Michael R Jaff; Timothy P Murphy; David J Cohen; Anthony J Comerota; Heather L Gornik; Mahmood K Razavi; Lawrence Lewis; Clive Kearon Journal: Am Heart J Date: 2013-03-05 Impact factor: 4.749
Authors: Suresh Vedantham; Thomas M Vesely; Gregorio A Sicard; Daniel Brown; Brian Rubin; Luis A Sanchez; Naveen Parti; Daniel Picus Journal: J Vasc Interv Radiol Date: 2004-06 Impact factor: 3.464
Authors: Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke Journal: Methodist Debakey Cardiovasc J Date: 2018 Jul-Sep
Authors: Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann Journal: Blood Adv Date: 2020-04-14
Authors: Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg Journal: Blood Adv Date: 2018-11-27